RDAF welcomes new board members in 2018

    4 Jun, 2018

    In May 2018, the General Assembly of the Rare Disease Action Forum (RDAF) elected the Forum’s board, welcoming two new board members: Ms. Rea Lal, Rare Disease Lead at Pfizer in Switzerland, and Dr. Jacqueline de Sá, General Secretary of the Swiss umbrella patient organization ProRaris. Rea Lal succeeds Dr. Roland Rutschmann, CEO at Curatis who did not run for reelection. The secretariat would like to thank Dr. Roland Rutschmann for the considerable expertise and great contributions he made as a board member since the founding of the RDAF. The new board composition reaffirms the multistakeholder approach of the Forum. The RDAF is looking forward to continuing its efforts to facilitate the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    RDAF hosts multi-stakeholder workshop on post-marketing registries

    The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...

    RDAF Newsletter

    We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include: Overview of the latest policy developments relevant for the rare disease field...